| Prof David Bates |
Anti-angiogenics |
|
Cancer therapeutics; chemoprevention; toxicology |
|
|
Chemical tools to interrogate cancer biology; cyclic peptide-based anti-cancer agents |
|
|
Annexins; anti-tumour agents; POT1 kinase; telomerase inhibitors |
|
|
Protein structure; x-ray crystallography |
|
|
Protein structure; x-ray crystallography |
|
|
Drug discovery oncology targets |
|
|
Structure-based drug design; telomere structure and targeting |
|
Dr Srinivasan
Madhusudan
|
DNA repair; base excision repair; APE1 inhibitors; stratified medicine;
cancer biomarkers |
|
|
Prognostic and predictive biomarkers; lymphatic biology and metastasis; radiation biology/radiotherapy; calpains and calpastatin |
|
|
Chemotherapy of cancer; molecular targeted agents; inhibitors of Hsp90; IDO; bioreductively activated agents; G-quadruplex ligands |
| Dr John Moses |
Chemical biology; click chemistry; drug discovery |
|
|
Protein structure using NMR |
| Dr Abdolrahman Shams-Nateri |
Cancer genetics and stem cell; transcription, signalling and diseases; transgenic mouse model |
|
|
Chemical synthesis; drug discovery in oncology |